BioAtla IPO Presentation Deck

BA3021: Encouraging Results in Stage IV PD-1 Refractory NSCLC Patients All evaluable NSCLC patients enrolled in BA3021 Phase 1 trial Maximum % Change from Baseline in Sum of Target Lesions 30% 20% 10% -10% -20% -30% -40% -50% -60% ■ ROR2 + **TmPS-100 ROR2- (**TmPS D Suboptimal dose (1.2mg/kg 2Q3W) ROR2 + Not (**TmPS-45) Evaluable Patient experienced tumor shrinkage prior to progression of metastatic bone lesions 1.2mg/kg d1,8 NSCLC squamous tumor: 10mm to 0mm on first scan 11.5mg/kg d1,8 ROR2 + 13.3mg/kg di * PR ROR2 + (**TmPS-70) 3mg/kg di bicatla Clinical results show promise in refractory patients 2 All NSCLC patients who enrolled in this trial had previously been treated with PD-1 therapy ROR2 expression strongly correlates with anti-tumor response Note: Not Evaluable (Strong, extensive fibroblastic stromal positivity reported) **TmPS= Tumor membrane Percent Score-Tumor membrane target expression calculated by summing the percentages of intensities at either 21+, 22+ or 23+, Scores range from 0 to 100, 17

View entire presentation